November 15, 2008 (Vol. 28, No. 20)

Aperio Technologies, a provider of systems and services for digital pathology to the healthcare and life sciences industries, joined with PDS Pathology Data Systems, which offers preclinical toxicology, pathology, and repro/teratology software, to develop an interface between Aperio’s Spectrum™ digital pathology information management system and PathData®, the PDS pathology software system.

The interface, which is expected to be complete in the summer of 2009, is designed to optimize laboratory workflow by providing access to true color whole-slide images at submicron resolution from within the PathData system, according to Aperio officials.

“Aperio’s digital format ensures that laboratories have on-demand access to pathology images wherever and whenever they need it,” says Dirk Soenksen, CEO of Aperio, who claims that this is the first commercial interface of its kind for preclinical workflow in pathology.

“Interfacing with PathData addresses the demands expressed by many of our pharmaceutical and CRO customers regarding the seamless integration of our Spectrum image management (PACS) software with leading LIMS,” continues Soenksen.

“Digital pathology provides an image-based environment for managing and interpreting information generated from a digitized glass slide, offering substantial improvements in preclinical pathology and drug discovery.”

“The PathData System offers the most advanced tools and technologies for laboratory information management, and the ability to give our pathology community seamless and efficient access to the cutting edge of whole slide imaging is an exciting development that will serve our mutual customers well,” adds Reto Aerni, CEO of PDS Pathology Data Systems. “The synergy created by the Aperio/PDS collaboration is a significant step in bringing whole-slide imaging into common use in the preclinical environment.”

Previous articlemiRNA Implicated in Inflammation Integral to Alzheimer’s Disease
Next articleUnited Therapeutics Pays $150M for Rights to Lily’s Tadalafil